「件」の検索結果
115件：106～110件目を表示
-
ガチフロ点眼液0.3%に関するよくあるご質問 | 医療関係者向製品情報（医療用医薬品） | 医療関係者のみなさま | 千寿製薬株式会社
に関する項目 5.分布 (3)乳汁への移行性 〈2025/01 作成〉 安全性 副作用一覧 承認時： 臨床試験での総症例429例中、副作用は25例（5.83％）に認められました。主な副作用は眼刺激12件（2.80％）、眼そう痒症6件（1.40％）でした。以下に承認時の副作用発現状況一覧を示します。 承認時：副作用発現状況一覧 調査症例数 429例 副作用等の発現症例数 25例 副作用発現症例率（％...
https://www.senju.co.jp/medical/faq/gatiflo.html -
·····························································································1 5．承認条件及び流通・使用上の制限事項······················································································...
https://www.senju.co.jp/system/files/2022-03/20220330_MKLA_IF.PDF -
·····························································································1 5．承認条件及び流通・使用上の制限事項······················································································...
https://www.senju.co.jp/system/files/2021-07/20210705_MK_IF.pdf -
·····························································································1 5．承認条件及び流通・使用上の制限事項······················································································...
https://www.senju.co.jp/system/files/2022-03/20220330_MKLA_IF_0.PDF -
·····························································································1 5．承認条件及び流通・使用上の制限事項······················································································...
https://www.senju.co.jp/system/files/2021-07/20210705_MK_IF_0.pdf